MMP3 and systemic sclerosis: The blockade and inactivation of α2AP by neutralizing antibodies, MMP-3, APCE inhibitor, miRNA, fusion proteins, and microplasmin may improve fibrosis progression, vascular dysfunction, and impaired fibrinolysis in SSc (Figure 5).